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ABSTRACT
Background: The PARP inhibitor olaparib was recently granted Food and Drug 
Administration (FDA) accelerated approval in patients with advanced BRCA1/2 
mutation ovarian cancer. However, antitumor responses are observed in only 
approximately 40% of patients and the impact of baseline clinical factors on response 
to treatment remains unclear. Although platinum sensitivity has been suggested as a 
marker of response to PARP inhibitors, patients with platinum-resistant disease still 
respond to olaparib.
Results: 108 patients with advanced BRCA1/2 mutation ovarian cancers were 
included. The interval between the end of the most recent platinum chemotherapy and 
PARPi (PTPI) was used to predict response to olaparib independent of conventional 
definition of platinum sensitivity. RECIST complete response (CR) and partial response 
(PR) rates were 35% in patients with platinum-sensitive versus 13% in platinum-
resistant (p<0.005). Independent of platinum sensitivity status, the RECIST CR/PR 
rates were 42% in patients with PTPI greater than 52 weeks and 18% in patients 
with PTPI less than 52 weeks (p=0.016). No association was found between baseline 
clinical factors such as FIGO staging, debulking surgery, BRCA1 versus BRCA2 
mutations, prior history of breast cancer and prior chemotherapy for breast cancer, 
and the response to olaparib.
Methods: We conducted an international multicenter retrospective study to 
investigate the association between baseline clinical characteristics of patients with 
advanced BRCA1/2 mutation ovarian cancers from eight different cancer centers and 
their antitumor response to olaparib.
Conclusion: PTPI may be used to refine the prediction of response to PARP 
inhibition based on the conventional categorization of platinum sensitivity.
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INTRODUCTION
The identification of BRCA1 and BRCA2 (BRCA1/2) 
genes has greatly enhanced our knowledge of the DNA 
repair pathways involved in cancer progression and 
has led to the exploitation of the concept of synthetic 
lethality in cancer therapy [1, 2]. Poly(ADP-ribose) 
polymerase (PARP) inhibitors were the first to translate 
this theory into clinical practice and promise a new 
strategy in personalizing cancer therapy. It is now 
more than ten years since the publication of the first 
preclinical evidence of PARP inhibitor synthetic lethality 
in BRCA1/2 mutation cancers. During this time, multiple 
clinical trials have investigated the clinical activity of 
different PARP inhibitors in a range of cancers. Olaparib 
(Lynparza; AstraZeneca) is the most extensively studied 
PARP inhibitor in patients with advanced BRCA1/2 
mutated ovarian cancer and has now received Food and 
Drug administration (FDA) and European Medicines 
Agency (EMA) regulatory approval in the relapsed and 
maintenance treatment settings, respectively.
The clinical activity of olaparib in patients with 
advanced germline BRCA1/2 mutation ovarian cancer has 
been assessed in a number of phase I/II trials. Overall, 
Response Evaluation Criteria In Solid Tumors (RECIST) 
complete or partial responses (CR/PR) or Gynecologic 
Cancer InterGroup (GCIG) CA125 antitumor responses 
ranged between 33%-59%, with a clinical benefit rate 
(RECIST or GCIG CA125 responses and RECIST stable 
disease) of 46-52% [3–7]. The antitumor efficacy of 
olaparib in recurrent ovarian cancer is currently being 
assessed in the randomized phase III SOLO-3 trial, which 
compares olaparib monotherapy to physician’s choice 
single-agent chemotherapy in patients with advanced 
BRCA1/2 mutated ovarian cancer (NCT02282020).
While phase I/II clinical trials with olaparib have 
reported impressive objective response rates in patients 
with advanced BRCA1/2 mutation ovarian cancer, not all 
patients achieve the same level of benefit to olaparib. This 
highlights the need to identify individual patient predictive 
biomarkers of response and resistance to guide treatment 
decisions. A number of translational clinical studies have 
now been initiated to identify molecular biomarkers of 
response to olaparib and other PARP inhibitors. Several 
studies are investigating the different molecular markers 
that might predict for antitumor response to olaparib 
and other PARP inhibitors beyond germline BRCA1/2 
mutations, including somatic BRCA1/2 mutations, 
functional classifiers of homologous recombination 
deficiency, gene expression profiling and genomic scarring 
signatures [8–12].
Earlier observations from limited clinical data 
suggested a potential relationship between prior sensitivity 
to platinum-based chemotherapy and antitumor responses 
to olaparib [4]. This has led us to investigate the baseline 
clinical characteristics of patients with advanced BRCA1/2 
mutation ovarian cancer, including the effects of platinum 
sensitivity as potential factors that may be used in the 
prediction of patients benefit to olaparib. In addition, we 
assessed the association between antitumor response to 
olaparib treatment and progression-free survival (PFS) and 
overall survival (OS).
RESULTS
Baseline characteristics
A total of 108 patients with germline BRCA1/2 
mutation advanced ovarian cancer from eight cancer 
centers who had been treated with olaparib at a dose of 
200mg BID or greater were included in our study (Table 
1). The median age of patients at enrolment to clinical 
trials was 55 years (range 38-79 years). The majority of 
patients (83 of 108; 77%) had high grade serous ovarian 
carcinoma. Other ovarian cancer subtypes included 
endometrioid (8 of 108; 7.4%), clear cell (9 of 108; 8.2%) 
and unknown histological subtypes (8 of 108; 7.4%). 
Staging at diagnosis was available for 98 of 108 patients: 
FIGO stage I (1 of 108, 0.9%), II (10 of 108, 9.3%), III (76 
of 108, 70.3%) and IV (11 of 108, 10.2%). FIGO staging 
was not available for 10 of 108 (9.3%) patients. Primary 
or interval surgical debulking data were available for 78 
of 108 (72.2%) patients. 58 (53.7%) patients had optimal 
debulking, while 20 (18.5%) patients had suboptimal 
debulking surgery at diagnosis. No surgical data were 
available for 30 (27.8%) patients. The median number 
of prior lines of chemotherapy for ovarian cancer before 
commencing treatment with olaparib was 3 (range 1-10). 
Of 108 patients, 65 (60.1%) were conventionally defined 
as platinum-sensitive, while 38 (35.2%) were platinum-
resistant at the time of starting olaparib. Platinum response 
status for 5 patients (4.6%) was not available. 77 of 108 
(71%) patients had germline BRCA1 mutations, while 31 
of 108 (29%) patients had germline BRCA2 mutations. 
Forty (38%) patients had a past history of breast cancer, 
of whom 20 (22.2%) received one previous line of 
chemotherapy for breast cancer.
Antitumor responses
Patients who only had one prior line of 
chemotherapy prior to receiving olaparib had significantly 
higher rates of RECIST CR/PR compared to those who 
received more than one prior line of treatment (p=0.005). 
No differences in RECIST CR/PR rates were noted 
between patients with germline BRCA1 (27.6%) mutations 
versus those with BRCA2 (27%) mutations (p=0.31). 
There was no association between having a past history of 
breast cancer or receiving prior chemotherapy for breast 
cancer, and achieving RECIST antitumor responses to 
olaparib (Table 2).
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The median PFS was 70 weeks for patients who had 
achieved RECIST CR/PR with olaparib therapy, compared 
to 28 weeks for patients without RECIST CR/PR (log-
rank, p=0.0004) (Figure 1A). Median OS was 161 weeks 
in patients with RECIST CR/PR, compared to 64 weeks 
in patients who did not achieve RECIST CR/PR (log-rank, 
p=0.0005) (Figure 1B).
Platinum sensitivity and antitumor response to 
olaparib
At the time of enrolment to each trial, 64% of 
patients were platinum sensitive, while 36% were 
platinum resistant. Higher likelihood of RECIST CR/PR 
rates were observed in patients with platinum-sensitive 
ovarian cancer (35%), in contrast to those with platinum-
resistant disease (13%) (p=0.02). Although the RECIST 
CR/PR rate was significantly lower in platinum-resistant 
patients compared to those with platinum-sensitive 
disease (13% versus 35%, p=0.02), 5 of 38 (13%) patients 
conventionally defined as platinum-resistant still achieved 
RECIST CR/PR, suggesting that platinum response status 
is not an absolute predictor of response to olaparib.
Influence of PTPI on response to olaparib
The median PTPI was 53 weeks (range 4-244 
weeks). Median PTPI was significantly longer for patients 
with platinum-sensitive ovarian cancer (68.7 weeks) 
compared to patients with platinum-resistant disease 
(25.9 weeks) (p<0.0001). Independent of their platinum 
response status, patients with PTPI of greater than 52 
weeks had higher CR/PR rates than those with PTPI of 
less than 52 weeks (42% vs 18%, respectively, p=0.016).
Table 1: Baseline Characteristics of patients with BRCA1/2 mutation advanced recurrent ovarian cancer treated 
with olaparib
Baseline Criteria N (%)
Study subjects 108
Age, Year Median (Range) 55 (38-79)
Tumor type
High grade serous 83 (77%)
Endometrioid 8 (7.4%)
Others 9 (8.2%)
Unknown 8 (7.4%)
Stage at diagnosis
1 1 (0.9%)
2 10 (9.3%)
3 76 (70.3%)
4 11 (10.2%)
Unknown 10 (9.3%)
Optimally debulked?
Yes 58 (53.7%)
No 20 (18.5%)
Unknown 30 (27.8%)
BRCA1/2 mutation
BRCA1 78 (79%)
BRCA2 30 (21%)
Past Medical History of Breast Cancer
Yes 40 (38%)
No 68 (62%)
Previous breast cancer chemotherapy
Yes 20 (18.5%)
No 88 (81.5%)
Platinum status at enrolment to 
Olaparib
Platinum-Sensitive 65 (60.1%)
Platinum-Resistant 38 (35.2%)
Unknown 5 (4.7%)
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Table 2: Association between baseline characteristics and antitumor responses to olaparib
Characteristic p
Platinum Status Plt-S (N=65) Plt-R (N=38)
Median PTPI 68.7w 25.9w p<0.0001
CR/PR to olaparib 23 (35%) 5 (13%) p=0.02
Prior lines of chemo 1 (N=15) >1 (N=91)
CR/PR to olaparib 8 (53.3%) 20 (23.5%) p<0.005
Platinum status and PTPI Plt-S >24w PTPI (N=58) Plt-R <24w PTPI (N=20)
CR/PR to olaparib 20 (34.5%) 2 (10%) p=0.04
PTPI (independent of Plt 
status) Pts with PTPI >52w (N=35) Pts with PTPI <52w (N=59)
CR/PR to olaparib 15 (42%) 11 (18%) p=0.016
BRCA1/2 status BRCA1 (N=77) BRCA2 (N=31)
CR/PR to olaparib 21 (27.6%) 7 (27%) p=0.31
Breast cancer history Prior BC (N=40) Without (N=68)
CR/PR to olaparib 17 (26.5%) 11 (29%) p= 0.76
Breast cancer 
chemotherapy Chemo (N=20) None (N=88)
CR/PR to olaparib 4 (22.2%) 24 (28.5%) p=0.64
In order to study the association of PTPI with 
response , we compared the RECIST response rate 
to olaparib in patients who were classed as platinum-
sensitive before commencing olaparib and had PTPI of 
greater than 24 weeks (‘best-responders’), to patients 
who were platinum-resistant and had PTPI of less than 
24 weeks (‘least-responders’). Fifty-eight patients 
were defined as ‘best responders’ and 20 patients as 
‘least responders’. The RECIST CR/PR rates achieved 
with olaparib with the ‘best responders’ group were 
significantly higher than the ‘least responders’ group 
(34.5% vs 10%, p=0.04). We did not identify any 
association between response to olaparib and other 
clinical baseline characteristics, including initial FIGO 
staging or cytoreductive surgery.
DISCUSSION
In this international multicenter retrospective study, 
we investigated the baseline clinical characteristics that 
may predict for antitumor responses to treatment with 
the PARP inhibitor olaparib in patients with advanced 
BRCA1/2 mutation ovarian cancer.
The hypothesis underlying the concept of synthetic 
lethality is that patients harboring deleterious germline 
BRCA1/2 mutations have homologous recombination 
deficient tumors, which may be treated effectively with 
PARP inhibitors [1, 2]. However, despite this, variable 
response rates to PARP inhibitors have been observed 
in patients with advanced germline BRCA1/2 mutation 
tumors, including those with ovarian cancer [3, 5, 6, 13, 
14]. Supplementary Table 1 summarises the different 
response rates observed in patients with advanced 
BRCA1/2 mutation ovarian cancer treated with olaparib 
in clinical trials. These trials confirmed the impressive 
activity of olaparib in patients with recurrent BRCA1/2 
mutant ovarian cancers, even in a proportion of patients 
with platinum-resistant disease [3–7]. A recent pooled 
analysis of data from six clinical trials with olaparib in 
BRCA1/2 mutation ovarian cancer patients has confirmed 
responses in both platinum sensitive and platinum resistant 
patients, but also describes a category of “platinum status 
unknown” (response rates in these 3 categories are 48%, 
28% and 35% respectively). The authors comment on the 
challenge of determining platinum status in platinum-
resistant patients who receive another non-platinum 
treatment which may be effective and are then treated with 
olaparib. [15].
A number of prospective and retrospective studies 
are currently ongoing to identify molecular biomarkers 
that may predict antitumor response to olaparib and 
other PARP inhibitors [8–12, 16]. While prior sensitivity 
to platinum-based chemotherapy has been reported to 
predict antitumor responses to olaparib, in our data set, 5 
(13%) platinum resistant patients responded to olaparib, 
suggesting that platinum sensitivity status may not be 
sufficiently robust as a predictor of response to olaparib. 
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Data from our study suggest that PTPI appears to be an 
additional clinical indicator of antitumor response to 
olaparib treatment, which may also be potentially 
applicable to other PARP inhibitors.
PTPI may be a useful indicator for informing both 
timing and sequence of non-platinum containing treatment 
regimens during the treatment journey of patients 
with advanced BRCA1/2 mutation ovarian cancer. Our 
data suggest that patients with a longer platinum-free 
interval, even after becoming resistant to platinum-based 
chemotherapies, are more likely to respond to olaparib 
and potentially other PARP inhibitors. This is consistent 
with some studies, which have suggested that a longer 
platinum-free interval may increase antitumor response 
rates to subsequent treatment, including rechallenging 
patients with platinum-based therapy [17, 18]. It may 
therefore be useful to modify the current classification 
of platinum sensitivity status, which is based on the 
response to the most recent platinum-based chemotherapy, 
which could be many months before the patients’ next 
treatment regimen. While we do not recommend using the 
PTPI as a sole clinical decision tool, the findings of this 
study warrants further investigation, ideally prospective 
validation, to assess the association of PTPI with response 
to olaparib and other PARP inhibitors in patients with 
advanced BRCA1/2 mutation ovarian cancers.
It has previously been speculated that the antitumor 
response to olaparib may be different in patients who have 
germline BRCA1 versus BRCA2 mutations [19]. In this 
retrospective study involving 78 patients with germline 
BRCA1 mutations and 30 with BRCA2 mutations, no 
differences in antitumor response was observed between 
both groups of patients. Details on the specific BRCA1/2 
gene mutations and their association with response to 
olaparib were not collected. This requires a larger series 
of patients that may further explain the lack of antitumor 
responses to PARP inhibitors in patients with advanced 
BRCA1/2 mutation ovarian cancer.
Despite this being one of the largest retrospective 
series of clinical data from patients with advanced 
Figure 1: (A) Median PFS is significantly improved for patients with RECIST responses (P-value for the trend =0.0004). (B) Median OS 
is significantly improved for patients with RECIST response (P-value for the trend =0.0005).
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BRCA1/2 mutation ovarian cancer treated with the PARP 
inhibitor olaparib, a limitation of this study was the 
involvement of a relatively small series of patients that 
prevented further statistical analysis such as regression 
analysis. Future studies with a larger data set will enable 
linear analysis to be undertaken to identify a more 
precise PTPI fit model to predict antitumor response to 
PARP inhibitors. The patients in our study have mostly 
undergone several lines of chemotherapy, so it is still 
possible that there is a population of either BRCA1 or 
BRCA2 patients who are excellent responders to first line 
chemotherapy and don't need olaparib or alternatively 
some who are very platinum resistant and don't survive 
to get olaparib.
The accelerated approval of olaparib by the FDA 
and EMA in patients with advanced BRCA1/2 mutation 
ovarian cancer (without specific platinum sensitivity 
status, FDA) heralded a new era in precision medicine 
in patients with advanced ovarian cancer. Several other 
PARP inhibitors are currently at different stages of clinical 
development in patients with BRCA1/2 mutation ovarian 
cancer. Despite this, improved strategies for selecting 
patients who may benefit most are urgently required, 
including clinical factors that can be implemented easily 
without additional delays, costs or logistical issues. We 
have shown that PTPI may potentially be an important 
clinical biomarker that should be considered when treating 
patients with advanced BRCA1/2 mutation ovarian cancer 
with a PARP inhibitor, and warrants further investigation 
either in conjunction with or independent of conventional 
platinum response status.
MATERIALS AND METHODS
Detailed clinical data were collected retrospectively 
from patient records of 108 patients with advanced recurrent 
germline BRCA1/2 mutation ovarian cancer from 8 cancer 
centers (Royal Marsden Hospital, UK; Edinburgh Centre, 
UK; University of California San Francisco, USA; Sheba 
Medical Centre, Israel; Prince of Wales Cancer Centre, 
Australia; Dana-Farber Cancer Institute, USA; Oncologisch 
Centrum UZ Brussel, Belgium; Princess Margaret Cancer 
Centre, Canada), which had participated in clinical trials 
of olaparib monotherapy between April 2006 and August 
2014. This study was approved by the Royal Marsden 
Clinical Research and Development Committee.
Only patients who had been treated with olaparib 
at doses of 200 mg tablet or capsule formulation or more 
twice daily in the relapsed setting were entered to this 
study. This minimum dose of 200 mg BID was selected 
on the basis of pharmacodynamic and antitumor activity 
of olaparib from previous studies, where doses of 200 mg 
BID resulted in significant target inhibition and antitumor 
responses [20, 21]. This study did not include any patient 
who had received olaparib in the maintenance treatment 
setting.
Baseline patient characteristics were collected 
and entered into a standardized database; these included 
details on demographics, surgical debulking, BRCA1/2 
status, prior chemotherapy, platinum-based chemotherapy 
sensitivity status at the time of enrolment, prior history 
of breast cancer or treatments received for breast cancer, 
RECIST and GCIG CA125 responses, survival, response 
rates and the interval between last platinum-based 
chemotherapy to the start of olaparib treatment.
Patients were defined as platinum-sensitive or 
platinum-resistant when the platinum-free interval was 
more than 12 months or less than 6 months, respectively 
[22]. Patients with a platinum-free interval of between 
6 to 12 months (partially platinum-sensitive) were also 
classified as platinum-sensitive in this study. Platinum-
containing chemotherapy was not necessarily the most 
recent antitumor treatment that patients had prior to 
receiving olaparib. We therefore also recorded the time 
interval between the end of last platinum-containing 
chemotherapy regimen and the start of olaparib treatment, 
termed the platinum-to-PARP inhibitor interval (PTPI), as 
a separate clinical parameter.
Pearson Chi2, odds ratios (OR) and Fisher’s exact 
probability tests were used for statistical analyses. Survival 
curves were generated using GraphPad Prism 6.
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